ACHIVEMENT
研究実績

著書・原著2022年度
原著

• 1. Kawakami S, Tsumura H, Satoh T, Tabata K, Sekiguchi A, Kainuma T, Nakano M, Iwamura M, Ishiyama H.
  : A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
  Radiation Oncology 17(1)：67, 2022 Apr.
• 2. Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H.
  : Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer.
  Radiation Oncology 17(1)：71, 2022 Apr.
• 3.Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H.
  : Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer.
  Scientific Reports 12(1)：11023, 2022 Jun.
• 4. Tomita N, Ishiyama H, Makita C, Ohshima Y, Nagai A, Baba F, Kuno M, Otsuka S, Kondo T, Sugie C, Kawai T, Takaoka T, Okazaki D, Torii A, Niwa M, Kita N, Takano S, Kawakami S, Matsuo M, Kumano T, Ito M, Adachi S,
  Abe S, Murao T, Hiwatashi A.
  : Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial.
  BMC Cancer 22(1)：1259, 2022 Dec.
• 5. Kawamura H, Nakamura K, Yoshioka Y, Itasaka S, Tomita N, Onishi M, Iwata H, Aizawa T, Kikuchi K, Nagata K, Nakamura K, Nishioka K, Ishiyama H, Ueno S, Kokubo M, Yamazaki H, Watanabe K, Toyoda T, Akimoto T ; JROSG Working Subgroup of Urologic Oncology.
  : Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey.
  Japanese Journal of Clinical Oncology 53(2)：146-152, 2023 Jan.

準原著

• 1.

総説・講座

• 1.

著書・原著2021年度
原著

• 1. Shibahara I, Miyasaka K, Sekiguchi A, Ishiyama H, Inukai M, Yasui Y, Watanabe T, Sato S, Hide T, Kumabe T.
  : Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
  Journal of Clinical Neuroscience 86：202-210, 2021 Apr.
• 2. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto KI, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H.；National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators.
  : Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
  Cancer Medicine 10(10)：3240-3248, 2021 May.
• 3. Ishiyama H, Tsumura H, Nagano H, Watanabe M, Mizuno E, Taka M, Kobayashi H, Eriguchi T, Imada H, Inaba K, Nakamura K.
  : Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients.
  Scientific Reports 11(1)：13194, 2021 Jun.
• 4. Yogo K, Murayama C, Hirayama R, Matsumoto KI, Nakanishi I, Ishiyama H, Yasuda H.
  : Protective Effects of Amino Acids on Plasmid DNA Damage Induced by Therapeutic Carbon Ions.
  Radiation Research 196(2)：197-203, 2021 Aug.
• 5. Yogo K, Tsuneda M, Horita R, Souda H, Matsumura A, Ishiyama H, Hayakawa K, Kanai T, Yamamoto S.
  : Three-dimensional dose-distribution measurement of therapeutic carbon-ion beams using a ZnS scintillator sheet.
  Journal od Radiation Research 62(5)：825-832, 2021 Sep.
• 6. Ishiyama H, Kawakami S, Sekiguchi A, Kainuma T, Miyamoto S, Yamashita T, Nakano M.
  : Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy.
  Scientific Reports 12(1)：2387, 2022 Feb.
• 7. Yogo K, Misawa M, Shimizu H, Kitagawa T, Hirayama R, Ishiyama H, Yasuda H, Kametaka S, Takami S.
  : Radiosensitization Effect of Gold Nanoparticles on Plasmid DNA Damage Induced by Therapeutic MV X-rays.
  Nanomaterials 12(5)：771, 2022 Feb.

準原著

• 1.

総説・講座

• 1.

著書・原著2020年度
原著

• 1. Katada C, Komori S, Yoshida T, Kawakami S, Watanabe A, Ishido K, Azuma M, Wada T, Hosoda K, Yamashita K, Hiki N, Tanabe S, Ishiyama H, Koizumi W.: A Retrospective Study of Definitive Chemoradiotherapy in Patients With Resectable Small Cell Neuroendocrine Carcinoma of the Esophagus. Esophagus., 17(2): 135-140, 2020 Apr.
• 2. Fukui T, Hosotani S, Soda I, Ozawa T, Kusuhara S, Kakegawa M, Kasajima M, Hiyoshi Y, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Ishiyama H, Naoki K.: Current Status and Progress of Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Prior to the Approval of Durvalumab., 11(4): 1005-1014, 2020 Apr.
• 3. Yogo K, Murayama  C, Fujisawa  Y, Maeyama T, Hirayama R, Ogawa Y, K Matsumoto,  Nakanishi I, Yasuda H, Ishiyama H, Hayakawa K.: Potential Mechanisms for Protective Effect of D-Methionine on Plasmid DNA Damage Induced by Therapeutic Carbon Ions., 193(6): 513-519, 2020 Jun.
• 4. Hagiwara Y, Nakayama Y, Kudo S, Hayakawa T, Nakamura N, Kitamoto Y, Takahashi S, Tsujino K, Kubo N, Tamaki Y, Nagata Y, Japan Radiation Oncology Study Group (JROSG) Working Subgroup for Lung and Mediastinal TumorsNationwide.: Nationwide Survey of Radiation Therapy in Japan for Lung Cancer Complicated With Interstitial Lung Disease. Journal of Radiation Research. 61(4): 563-574, 2020 Jul.
• 5. Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Takezawa Y, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi  M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Yamanaka H, National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer Investigators.: Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. Cancer., 126(17): 3961-3971, 2020 Sep.
• 6. Harada H, Yamashita K, Katada C, Ishiyama H, Soeno T, Washio M, Sakuraya M, Ushiku H, Niihara M, Hosoda K, Hiki N.: Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma. Langenbeck's Archives of Surgery., 405(6): 767-776, 2020 Sep.
• 7. Hayakawa T, Hayakawa K, Soda I, Sekiguchi A, Kawakami S, Sasaki J, Naoki K, Ishiyama H.: Clinical outcomes and prognostic factors of limited-stage small cell lung cancer patients treated with chemoradiotherapy: a single-institutional study. Kitasato Medical Journal., 50(2): 130-137, 2020 Sep.
• 8. Hayakawa T, Tabata K, Tsumura H, Kawakami S, Katakura T, Hashimoto M, Watanabe Y, Iwamura M, Hasegawa T, Ishiyama H.: Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients. Japanese Journal of Radiology., 38(10): 993-996 , 2020 Oct.
• 9. Kubota Y, Katada C, Yoshida T, Wada T, Hosoda K, Kawakami S, Ishido K, Watanabe A,  Yamashita K, Ishiyama H, Hiki N, Tanabe S, Koizumi W.: Multiple gastrointestinal metastasis after endoscopic submucosal dissection for poorly differentiated gastric adenocarcinoma. Clin J Gastroenterol., 13(5): 717-721, 2020 Oct.
• 10. Yogo K, Noguchi Y, Okudaira K, Nozawa M, Ishiyama H, Okamoto H, Yasuda H, Oguchi H, Yamamoto S.: Source position measurement by Cherenkov emission imaging from applicators for high‐dose‐rate brachytherapy. Medical Physics 48(1)：488-499, 2021 Jan. Epub, 2020 Dec.
• 11. Yogo K, Misawa M, Shimizu M, Shimizu H, Kitagawa T, Hirayama R, Ishiyama H, Furukawa T, Yasuda H.: Effect of Gold Nanoparticle Radiosensitization on Plasmid DNA Damage Induced by High-Dose-Rate Brachytherapy.International Journal of Nanomedicine 16：359-370, 2021 Jan.

準原著

• 1.

著書

• 1.

総説・講座

• 1. 石山博條. : 癌治療におけるパラダイムの変遷　乳癌を中心とした医学史的考察. 北里医学, 50(1): 9-18, 2020.

著書・原著2019年度
原著

• 1. Ishiyama H, Shuto N, Terazaki T, Noda S, Ishigami M, Yogo K, Hayakawa K.: Risk factors for r+B45:B78adiotherapy incidents: a single institutional experience. Med Dosim., 44(1):26-29,2019 Spring.
• 2. Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.: Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study. Prostate., 79(5): 506-514,2019 Apr.
• 3. Sekiguchi A, Tsumura H, Kawakami S, Satoh T, Iwamura M, Ishiyama H.: Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis. International Journal of Urology., 26(9): 938-939, 2019 Sep.
• 4. Kainuma T, Kawakami S, Tsumura H, Satoh T, Tabata K, Iwamura M, Hayakawa K, Ishiyama H.: A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer. Radiat Oncol., 14(1): 158, 2019 Sep.
• 5. Koga H, Naito S, Ishiyama H, Yorozu A, Saito S, Kojima S, Higashide S, Kikuchi T, Nakamura K, Dokiya T, Fukushima M, J-POPS Study Group.: Patient-reported Health-Related Quality of Life Up to Three Years After the Treatment With Permanent Brachytherapy: Outcome of the Large-Scale, Prospective Longitudinal Study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS). Brachytherapy., 18(6): 806-813, 2019 Nov-Dec.
• 6. Hayakawa T, Kawakami S, Soda I, Kainuma T, Nozawa M, Sekiguchi A, Miyamoto S, Yamashita T, Ishiyama H.: Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer. Radiation Oncology., 14(1): 221, 2019 Dec.
• 7. Murakami Y, Satoh T, Tsumura H, Tabata K, Matsumoto K, Ishiyama H, Iwamura M.: Quality of Life Outcomes After Low Dose-Rate Brachytherapy for Localized Prostate Cancer: Current Status and Future Perspectives. International Journal of Urology., 26(12): 1099-1105, 2019 Dec.
• 8. Yogo K, Matsushita A, Tatsuno Y, Shimo T, Hirota S, Nozawa M, Ozawa S, Ishiyama H, Yasuda H, Nagata Y, Hayakawa K.: Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy. Scientific Reports., 10(1): 3572, 2020 Feb.

準原著

• 1.

著書

• 1.

総説・講座

• 1.

著書・原著2018年度
原著

• 1. Nakahara Y, Sasaki J, Fukui T, Otani S, Igawa S, Hayakawa K, Masuda N.: The role of prophylactic cranial irradiation for patients with small-cell lung cancer. Jpn J Clin Oncol., 48(1):26-30,2018 Jan.
• 2. Kubo M, Satoh T, Ishiyama H, Tabata KI, Tsumura H, Komori S, Iwamura M, Baba S, Hayakawa K, Kawamura T, Obata F.: Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy. Oncol Rep., 39(1):417-424,2018 Jan.
• 3. Ishiyama H, Tsumura H, Kawakami S, Satoh T, Sekiguchi A, Tabata KI, Iwamura M, Hayakawa K.: A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial. J Contemp Brachytherapy., 10(1): 10-16, 2018 Feb.
• 4. Watanabe A, Katada C, Komori S, Moriya H, Yamashita K, Harada H, Azuma M, Kondo Y, Kubota Y, Furue Y, Kawanishi N, Yamane S, Wada T, Yano T, Ishido K, Tanabe S, Hayakawa K, Koizumi W.: Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study. Adv Radiat Oncol., 3(3):305-313,2018 Mar.
• 5. Mohri J, Katada C, Ueda M, Sugawara M, Yamashita K, Moriya H, Komori S, Hayakawa K, Koizumi W, Atsuda K.: Predisposing Factors for Chemotherapy-induced Nephrotoxicity in Patients with Advanced Esophageal Cancer Who Received Combination Chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil. J Transl Int Med., 6(1):32-37,2018 Mar.
• 6. Teh BS, Lewis GD, Mai W, Pino R, Ishiyama H, Butler EB.: Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Cancer Commun (Lond)., 38(1):11,2018 Apr.
• 7. Okamoto T, Katada C, Komori S, Yamashita K, Miyamoto S, Kano K, Seino Y, Hosono H, Matsuba H, Moriya H, Sugawara M, Azuma M, Ishiyama H, Tanabe S, Hayakawa K, Koizumi W, Okamoto M, Yamashita T.: A retrospective study of treatment for curative synchronous double primary cancers of the head and neck and the esophagus. Auris Nasus Larynx., 45(5):1053-60,2018 Oct.

準原著

• 1.

著書

• 1.

総説・講座

• 1.

著書・原著2017年度
原著

• 1. Tsumura H, Satoh T, Ishiyama H, Tabata KI, Takenaka K, Sekiguchi A, Nakamura M, Kitano M, Hayakawa K, Iwamura M.: Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. Int J Mol Sci., 18(1). pii: E128, 2017 Jan 11.
• 2. Katoh N, Soda I, Tamamura H, Takahashi S, Uchinami Y, Ishiyama H, Ota K, Inoue T, Onimaru R, Shibuya K, Hayakawa K, Shirato H.: Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. Radiat Oncol., 12(1):3, 2017 Jan.
• 3. Yogo K, Tatsuno Y, Tsuneda M, Aono Y, Matsushita A, Ishigami M, Ishiyama H, Hayakawa K.: Practical use of a plastic scintillator for quality assurance of electron beam therapy. Phys Med Biol., 62(11):4551-4570,2017 Jun.
• 4. Nakamura T, Sato T, Hayakawa K, Takayama Y, Naito M, Yamanashi T, Tsutsui A, Miura H, Watanabe M.: Risk factors for perineal wound infection after abdominoperineal resection of advanced lower rectal cancer. Ann Med Surg (Lond)., 15:14-18,2017 Feb.
• 5. Yamane S, Katada C, Tanabe S, Azuma M, Ishido K, Yano T, Wada T, Watanabe A, Kawanishi N, Furue Y, Kondo Y, Komori S, Ishiyama H, Hayakawa K, Koizumi W.: Clinical outcomes in patients with cancer of unknown primary site treated by gastrointestinal oncologists. Journal of Translational Internal Medicine., 5(1):58-63,2017 Mar.
• 6. Yamashita K, Hosoda K, Moriya H, Katada C, Sugawara M, Mieno H, Komori S, Katada N, Watanabe M.: Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence. Oncology., 92(4):221-228,2017 Apr.
• 7. Ishiyama H, Kamitani N, Kawamura H, Kato S, Aoki M, Kariya S, Matsumura T, Kaidu M, Yoshida K, Hashimoto Y, Noda Y, Lim KH, Kawase T, Takahashi T, Inaba K, Kumano M, Yoshikawa N, Yoshioka Y, Nakamura K, Hiratsuka J, Itami J, Hayakawa K.: Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Brachytherapy., 16(3):503-510,2017 May-Jun.
• 8. Ishihara M, Igawa S, Sasaki J, Otani S, Fukui T, Ryuge S, Katono K, Hiyoshi Y, Kasajima M, Mitsufuji H, Kubota M, Yokoba M, Katagiri M, Sekiguchi A, Soda I, Ishiyama H, Hayakawa K, Masuda N.: Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. Oncol Lett., 14(1):885-890,2017 Jul.
• 9. Ishiyama H, Nakano M, Toya K, Kota R, Kikuchi K, Yamaguchi T, Kono N, Kawakami S, Tsutsumi Y, Tanaka T, Eriguchi T, Ohga S, Yamaguchi T, Takakawa Y, Morita M, Katayama N, Ohashi T, Aoki M, Yorozu A, Saito S.: Variability of treatment planning of seed implantation: A Japanese multicenter simulation study. Brachytherapy., 16(5): 1013-1020,2017 Sep - Oct.
• 10. Kawakami S, Ishiyama H, Satoh T, Tsumura H, Sekiguchi A, Takenaka K, Tabata KI, Iwamura M, Hayakawa K.: Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy. J Contemp Brachytherapy., 9(4):316-322,2017 Aug.
• 11. Komori S, Katada C, Sugawara M, Takahashi K, Yamashita K, Tanabe S, Koizumi W, Hayakawa K.: Retrospective evaluation of the feasibility of definitive chemoradiotherapy after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma. Kitasato Med J., 47(2):118-128,2017 Sep.
• 12. Yamazaki T, Kodaira T, Ota Y, Akimoto T, Wada H, Hiratsuka J, Nishimura Y, Ishihara S, Nonoshita T, Hayakawa K, Sekii S, Uchida N.: Retrospective analysis of definitive radiotherapy for neck node metastasis from unknown primary tumor: Japanese Radiation Oncology Study Group study. Jpn J Clin Oncol., 47(9):856-862,2017 Sep.
• 13. Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, Komori S, Yoshida T, Tanabe S, Koizumi W, Katada N, Watanabe M.: Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today., 47(10):1249-1258,2017 Oct.
• 14. Hayakawa T, Nonaka T, Mizoguchi N, Hagiwara Y, Shibata S, Sakai R, Nakayama N, Yokose T, Nakayama Y.: Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum: a case report. Clin J Gastroenterol., 10(5):431-436,2017 Oct.
• 15. Tsumura H, Ishiyama H, Tabata KI, Katsumata H, Kobayashi M, Ikeda M, Kurosaka S, Fujita T, Kitano M, Satoh T, Yanagisawa N, Hayakawa K, Iwamura M.: Impact of five‐tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high‐dose‐rate brachytherapy. Prostate., 77(15):1520-27,2017 Nov.
• iibe Y, Onda T, Matsuo K, Inoue Y, Hayakawa K.: Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results. Anticancer Res., 37(12):6983-88,2017 Dec.

準原著

• 1.

症例・研究報告

• 早田格,早川和重,石山博條,三宅俊之,市邉義章,清水公也. Radiation therapy for sebaceous carcinoma of the eyelid: a case report. The Kitasato Medeical Journal, 47(1): 78 -80, 2017.

著書

• 1.

総説・講座

• 1. 佐藤威文, 石山博條. 【高齢者の泌尿器疾患-病態に基づく診断・治療上の問題-】 高齢者泌尿器悪性疾患の病態と治療　転移性前立腺癌に対する新しい総合的治療戦略. 日本臨床, 75(4): 620-625, 2017.
• 2. 名木渉人, 佐藤威文, 石山博條, 津村秀康, 田畑健一, 志村 哲, 早川和重, 岩村正嗣：【前立腺癌患者の性機能を考える】 外照射後の性機能. Prostate Journal, 4(1):33-37, 2017.
• 3. 津村秀康, 佐藤威文, 田畑健一, 石山博條, 関口茜衣：前立腺癌密封小線源療法における血中循環腫瘍細胞に関する研究. 泌尿器外科, 30(8): 1241-1242, 2017.
• 4. 佐藤威文, 津村秀康, 田畑健一, 石山博條.：専門医試験に役立つ前立腺知識　前立腺癌治療中の骨マネジメント. Prostate Journal, 4(2): 281-287, 2017.

著書・原著2016年度
原著

• 1. Ishiyama H, Satoh T, Yorozu A, Saito S, Kataoka M, Hashine K, Nakamura R, Tanji S, Masui K, Okihara K, Ohashi T, Momma T, Aoki M, Miki K, Kato M, Morita M, Katayama N, Nasu Y, Kawanaka T, Fukumori T, Ito F, Shiroki R, Baba Y, Inadome A, Yoshioka Y, Takayama H, Hayakawa K.: Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy. J Radiat Res., 57(1):68-74, 2016 Jan.
• 2. Ishido K, Higuchi K, Tanabe S, Azuma M, Sasaki T, Katada C, Komori S, Hayakawa K, Hosoda K, Yamashita K, Katada N, Koizumi W.: Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol., 34(1):35-42, 2016 Jan.
• 3. Ishiyama H, Sekiguchi A, Satoh T, Tsumura H, Takenaka K, Kawakami S, Tabata K, Kobayashi K, Iwamura M, Hayakawa K.: Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS. J Contemp Brachytherapy., 8(1):7-16. 2016 Feb.
• 4. Sato T, Hayakawa K, Tomita N, Noda M, Kamikonya N, Watanabe T, Kato D, Sakai Y, Hiraoka M, Shimada M, Ikushima H, Baba H, Oya N, Oya M, Nemoto-Murofushi K, Takeuchi M, Watanabe M.: A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). Radiother Oncol., 120(2):222-7, 2016 Aug.
• 5. Tsumura H, Satoh T, Ishiyama H, Tabata K, Komori S, Sekiguchi A, Ikeda M, Kurosaka S, Fujita T, Kitano M, Hayakawa K, Iwamura M.: Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. J Contemp Brachytherapy., 8(2):95-103, 2016 Apr.
• 6. Ohba A, Kato K, Ito Y, Katada C, Ishiyama H, Yamamoto S, Ura T, Kodaira T, Kudo S, Tamaki Y.: Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial.Adv Radiat Oncol.,1(4):230-236.2016 Jul .

準原著

• 1.

著書

• 1. 石山博條：10．放射線療法（組織内照射）.前立腺癌診療ガイドライン2016年版. メディカルレビュー社, 大阪、2016、pp167-169.

総説・講座

• 1. 早川和重：局所進行肺癌への放射線治療．Current Therapy，ライフメディコム，愛知，2016，第34巻5号，442-448頁．
• 2. 早川和重：肺癌放射線療法が目指す長期生存：放射線腫瘍医が目指す長期生存とは．日本胸部臨床，克誠堂出版，東京，2016年7月，第75巻7号，749-757頁．
• 3. 佐藤威文, 石山博條. 【前立腺癌-基礎・臨床研究の最新知見-】 最新の臨床研究　前立腺癌骨転移の診断と集学的治療の最新知見. 日本臨床, 74(1):129-136, 2016.
• 4. 立花貴史, 佐藤威文, 津村秀康, 田畑健一, 柳澤信之, 原 敏将, 石山博條, 野村 恵, 坂田裕介, 綿貫 翔, 師尾繁孝, 岩村正嗣： 前立腺癌局所治療後再発の診断と治療　再発後の根治の可能性を探る 前立腺癌局所治療後の局所再発診断ストラテジー. 泌尿器外科, 29: 843-845, 2016.

著書・原著2015年度
原著

• 1. Nakashima H, Jiang SX, Sato Y, Hoshi K, Matsumoto T, Nagashio R, Kobayashi M, Matsuo Y, Shiomi K, Hayakawa K, Saegusa M, Satoh Y.: Prevalent and up-regulated vimentin expression in micropapillary components of lung adenocarcinomas and its adverse prognostic significance. Pathol Int., 65(4):183-192, 2015 Apr.
• 2. Soda I, Ishiyama H, Ono S, Takenaka K, Arai M, Arai T, Iwase H, Sekiguchi A, Kawakami S, Komori S, Onda T, Hayakawa K: Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy? J Radiat Res., 56(2):354-9, 2015 Mar.
• 3. Ishiyama H, Satoh T, Sekiguchi A, Tabata K, Komori S, Tsumura H, Kawakami S, Soda I, Takenaka K, Iwamura M, Hayakawa K.: Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer. J Contemp Brachytherapy., 7(1):3-9, 2015.
• 4. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, Shioyama Y, Onimaru R, Kozuka T, Kunieda E, Saito T, Nakagawa K, Hareyama M, Takai Y, Hayakawa K, Mitsuhashi N, Ishikura S.: Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys., 93(5):989-96, 2015.
• 5. Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata K, Kurosaka S, Matsumoto K, Fujita T, Kitano M, Baba S, Hayakawa K, Iwamura M.: Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol., 7(12):494-500, 2015.
• 6. Satoh T, Dokiya T, Yamanaka H, Saito S, Ishiyama H, Itami J, Shibuya H, Nakano T, Shigematsu N, Aoki M, Egawa S, Hashimoto M, Nishimura T, Yorozu A.: Postmortem radiation safety and issues pertaining to permanent prostate seed implantation in Japan. Brachytherapy., 14(2):136-41,2015 Mar-Apr.

準原著

• 1.

著書

• 1. 早川和重：日本臨床腫瘍学会編：新臨床腫瘍学（改訂第4版）．南江堂,東京，編集委員．
• 2. Hayakawa K: International Experience. In “Stereotactic Body Radiation Therapy: Principles and Practices (Nagata Y ed.)”, Springer Japan., 2015, pp151-162
• 3. 関口茜衣，早川和重：血液疾患と放射線療法．血液内科クリニカルスタンダード―必携ベッドサイドで必ず役立つ臨床血液学のエッセンス 第３版（東原正明，須永真司編)，文光堂，東京，2015，92-97頁．

総説・講座

• 1. 津村秀康，佐藤威文，石山博條，田畑健一，北野雅史，黒坂眞二，関口茜衣，川上正悟，小森承子，早川和重，岩村正嗣：Very-high-risk前立腺癌に対する内分泌療法と外部照射併用によるHDR brachytherapyの有用性．泌尿器外科，医学図書出版，東京，2015，第28巻臨時増刊号，623-625頁．
• 2. 早川和重：大腸癌に対する放射線治療の意義と応用．医学のあゆみ，医歯薬出版，東京，2015，第253巻10号，1059-64頁．
• 3. 早川和重：肺がんの治療法を知る：放射線療法．がん看護，南江堂，東京，2015，第20巻6号，613-615頁．
• 4. 早川和重，高井良尋：有害事象をいかに防止するか？：はじめに．臨床放射線，金原出版，東京，2015，第60巻10号，1205-7頁．
• 5. 平野修平, 佐藤威文, 石山博條, 北野雅史, 津村秀康, 田畑健一, 小林健太郎, 望月康平, 金子志保, 関口茜衣, 川上正悟, 竹中浩二, 早川和重, 馬場 志郎, 岩村正嗣： 高リスク限局性・局所浸潤前立腺がんの治療戦略 HDRブラキセラピーの意義. 泌尿器外科, 28(8):1433-1435, 2015.